{
  "report_rows": [
    {
      "kpi": "Q2 2026 total revenue",
      "prediction": "BEAT",
      "answer": "pred ~$1.72B vs. cons $1.70B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 TAVR revenue",
      "prediction": "BEAT",
      "answer": "pred ~$1.245B vs. cons $1.230B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 TMTT revenue",
      "prediction": "BEAT",
      "answer": "pred ~$192M vs. cons $187M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Total sales growth",
      "prediction": "BETTER",
      "answer": "guide ~10.5% vs. cons 10.0% (FY 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "TAVR sales growth",
      "prediction": "BETTER",
      "answer": "guide ~8.5% vs. cons 8.2% (FY 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted EPS",
      "prediction": "UNCHANGED",
      "answer": "guide ~$3.03 vs. cons $3.03 (FY 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total revenue",
      "prediction": "LOWER",
      "answer": "guide ~$1.71B vs. cons $1.72B (Q3 2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "Adjusted EPS",
      "prediction": "LOWER",
      "answer": "guide ~$0.72 vs. cons $0.74 (Q3 2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 3.2,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.4,
  "day5_path": "FADE",
  "day5_rationale": "Broad Q2 product-sales beats and modest FY growth upgrades support the initial move, but Q3 adjusted EPS guidance of ~$0.72 versus $0.74 consensus implies a ~$0.02 out-period shortfall; FY adjusted EPS of ~$3.03 versus $3.03 consensus leaves limited upward revision capacity, causing part of the day-1 gain to fade.",
  "day5_confidence": "MEDIUM"
}